Human Nutrition & Health | Animal Nutrition &
Exhibit 99.1 Human Nutrition & Health | Animal Nutrition & Health | Specialty Products
Balchem Corporation Reports Third Quarter 2026 Financial Results Montvale, NJ, October 23, 2026 - Balchem Corporation (NASDAQ: BCPC) today reported financial results for its 2026 fiscal third quarter ended September 30, 2026. For the quarter, the Company reported net sales of $290.7 million, net earnings of $46.7 million, adjusted EBITDA (a) of $80.3 million, and free c ash flow (a) of $57.9 million.
Ted Harris, Chairman, President and CEO of Balchem, said, “Balchem delivered another excellent quarter, with healthy growth across all three of our reporting segments and record consolidated quarterly net sales, net earnings, and adjusted EBITDA.”
• Net sales were $290.7 million, an increase of 8.6% from the prior year quarter.
• GAAP net earnings were $46.7 million, an increase of 16.0% from the prior year quarter.
• Adjusted EBITDA was $80.3 million, an increase of 12.4% from the prior year quarter.
• GAAP earnings per share were $1.46 compared to $1.24 in the prior year quarter and adjusted earnings per share (a) were $1.57 compared to $1.35 in the prior year quarter.
• Cash flows from operations were $69.8 million, with free cash flow of $57.9 million.
• Sales and earnings from operations growth in all three of our reporting segments.
• At the upcoming SupplySide Global trade show, we will showcase several of our latest Human Nutrition and Health technologies and innovations, including new science supporting VitaCholine ® , K2VITAL ™ , Optifolin+ ® and OptiMSM ® , as well as advances in performance nutrition and functional food and beverage applications. These innovations highlight the strength of our pipeline and our continued focus on developing differentiated, science-backed solutions that address important human health and wellness trends.
• Balchem repurchased approximately $28 million of common stock during the third quarter and approximately $127 million over the trailing twelve months, reflecting the Company's balanced capital allocation strategy and commitment to long-term shareholder value creation.
Mr. Harris added, “With strong results through the first nine months of the year and a healthy balance sheet, Balchem is well positioned to continue executing our strategic growth initiatives, and we remain excited about the future of our company.”
(a) See “Non-GAAP Financial Information” for a reconciliation of GAAP and non-GAAP financial measures.
segment generated record quarterly sales of $188.2 million, an increase of $14.1 million, or 8.1%, compared to the prior year quarter. The increase was driven by higher sales within both the nutrients business and the food ingredients and solutions businesses. Record earnings from operations for this segment of $45.6 million increased $4.8 million, or 11.8%, compared to $40.8 million in the prior year quarter, primarily due to the aforementioned higher sales and favorable mix, partially offset by higher operating expenses. Excluding the effect of non- cash expense associated with amortization of acquired intangible assets and other adjustments, record adjusted earnings from operations (a) for this segment were $48.9 million, compared to $44.1 million in the prior year quarter, an increase of 10.9%.
segment generated quarterly sales of $63.0 million, an increase of $6.6 million, or 11.7%, compared to the prior year quarter. The increase was driven by higher sales in both the monogastric and ruminant species markets. Third quarter earnings from operations for this segment of $6.8 million increased $3.1 million, or 82.8%, compared to $3.7 million in the prior year quarter, primarily due to the aforementioned higher sales and favorable mix, partially offset by certain higher manufacturing input costs. Excluding the effect of non-cash expense associated with amortization of acquired intangible assets and other adjustments, adjusted earnings from operations for this segment were $7.0 million compared to $4.0 million in the prior year quarter, an increase of 73.6%.
segment generated quarterly sales of $37.3 million, an increase of $1.6 million, or 4.5%, compared to the prior year quarter, due to higher sales in the performance gases business. Earnings from operations for this segment of $12.3 million increased $0.8 million, or 6.6%, compared to $11.5 million in the prior year quarter, primarily driven by the aforementioned higher sales and favorable mix, partially offset by higher operating expenses. Excluding the effect of non- cash expense associated with amortization of acquired intangible assets and other adjustments, adjusted earnings from operations for this segment were $13.1 million, compared to $12.7 million in the prior year quarter, an increase of 3.0%.
Consolidated quarterly gross margin of $105.7 million increased by $10.3 million, or 10.7%, compared to $95.5 million for the prior year comparable period. Gross margin as a percentage of sales was 36.4% compared to 35.7% in the prior year period, an increase of 70 basis points, primarily due to sales growth, favorable mix and manufacturing efficiencies, partially offset by certain higher manufacturing input costs. Operating expenses of $43.3 million for the quarter increased $2.4 million from the prior year comparable quarter, primarily due to higher compensation-related costs, partially offset by the net favorable impact of certain discrete items.
Net interest expense was $1.9 million and $2.6 million in the third quarters of 2026 and 2025, respectively. The decrease in interest expense was primarily due to lower outstanding borrowings and lower interest rates. Our effective tax rates for the three months ended September 30, 2026 and 2025 were 22.2% a nd 22.6%, respectively . The decrease in the effective tax rate was primarily d ue to higher favorable adjustments related to the filing of the prior year federal tax return and a higher foreign-derived intangible income deduction benefit, partially offset by an increase in certain state taxes.
Third quarter cash flows provided by operating activities were $69.8 million and free cash flow was $57.9 million. Net working capital of $240.8 million as of September 30, 2026 included a cash balance of $66.3 million. Significant cash payments during the quarter included net debt payments of $28.0 million, income taxes paid of $27.8 million, repurchases of common stock of $27.4 million, and capital expenditures and intangible assets acquired of $12.5 million. Outstanding debt on our revolving loan was $124.0 million as of September 30, 2026 and our net debt (b) was $57.7 million, with an overall leverage ratio (c) on a net debt basis of 0.2 times.
Mr. Harris said, “The Balchem team delivered another strong quarter in Q3 of 2026, and we remain confident in the long-term growth outlook for our company as we continue to execute our strategic growth initiatives.”
(b) Net debt is defined as the outstanding balance on our revolving loan less cash and cash equivalents. (c) Leverage ratio is defined as net debt divided by trailing twelve months adjusted EBITDA.
A quarterly conference call will be held on Friday, October 23, 2026, at 11:00 AM Eastern Time (ET) to review third quarter 2026 results. Ted Harris, Chairman, President and CEO and Martin Bengtsson, CFO, will host the call. Institutional investors, analysts and other members of the financial community are invited to join the live call by dialing +1-833-461-5787 (USA/Canada toll free) or +1-585-542-9983 (International Toll), and referencing Meeting ID: 831870284, five minutes prior to the scheduled start time of the conference call. Investors and the public are invited to listen to the live webcast at https://events.q4inc.com/attendee/831870284. The conference call will be available for replay shortly after the conclusion of the call at https://events.q4inc.com/attendee/831870284 for one year.
Balchem Corporation reports three business segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The Human Nutrition and Health segment delivers customized food and beverage ingredient systems, as well as key nutrients into a variety of applications across the food, supplement and pharmaceutical industries. The Animal Nutrition and Health segment manufactures and supplies products to numerous animal health markets. Through Specialty Products, Balchem provides specialty-packaged performance gases for use in healthcare and other industries, and also provides chelated minerals to the micronutrient agricultural market. Sales and production of products outside of our reportable segments and other minor business activities are included in "Other and Unallocated".
This release contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, which reflect our expectation or belief concerning future events that involve risks and uncertainties. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "forecast," "outlook," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," or the negative thereof or variations thereon or similar expressions generally intended to identify forward-looking statements. Forward-looking statements may relate to such matters as projections of revenue, margins, expenses, tax provisions, earnings, cash flows, benefit obligations, dividends, share repurchases or other financial items; any statements of the plans, strategies and objectives of management for future operations, including those relating to any statements concerning expected development, performance or market share relating to our products and services; any statements regarding future economic conditions or our performance; any statements regarding pending investigations, claims or disputes; any statements of expectation or belief; and any statements of assumptions underlying any of the foregoing. These statements are based on the Company's currently available information and our current assumptions, expectations and projections about future events. They are subject to future events, risks and uncertainties - many of which are beyond the Company’s control - as well as potentially inaccurate assumptions, that could cause actual results to differ materially from those in the forward-looking statements. Important factors and other risks that may affect the Company's business or that could cause actual results to differ materially are included in filings the Company makes with the U.S. Securities and Exchange Commission from time to time, including its Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q, its Current Reports on Form 8-K, and in its other SEC filings. Reference should be made to such factors and all forward-looking statements are qualified in their entirety by the above cautionary statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Contact: Jacqueline Yarmolowicz, Balchem Corporation (Telephone: 845-326-5600)
Nine Months Ended Cash flows from September 30, operating activities: 2026 2025 ────────────────────────────────────────────────────────────────────────────── Net earnings $ 131,628 $ 115,620 Adjustments to reconcile net earnings to net cash provided by operating activities: Depreciation and 37,100 33,969 amortization Stock compensation 16,316 14,298 expense Other adjustments 3,037 -1,692 Changes in assets and -31,537 -12,914 liabilities Net cash provided by operating 156,544 149,281 activities Cash flows from investing activities: Capital expenditures and intangible -29,605 -27,275 assets acquired Cash paid for acquisitions, net of — -323 cash acquired Proceeds from the sale 7 267 of assets Investment in -155 -144 affiliates Net cash used in -29,753 -27,475 investing activities Cash flows from financing activities: Proceeds from 88,000 70,000 revolving loan Principal payments on -128,000 -106,000 revolving loan Principal payments on -153 -145 finance leases Cash paid for -1,943 — financing costs Proceeds from stock 11,589 6,867 options exercised Dividends paid -30,773 -28,276 Repurchases of common -71,925 -54,008 stock Net cash used in -133,205 -111,562 financing activities Effect of exchange -1,892 5,334 rate changes on cash (Decrease) increase in cash and cash -8,306 15,578 equivalents Cash and cash equivalents, beginning 74,570 49,515 of period Cash and cash equivalents, end of $ 66,264 $ 65,093 period
In addition to disclosing financial results in accordance with United States (U.S.) generally accepted accounting principles (GAAP), this earnings release contains non-GAAP financial measures that we believe are helpful in understanding and comparing our past financial performance and our future results. The non-GAAP financial measures in this press release include adjusted gross margin, adjusted earnings from operations, adjusted net earnings and the related adjusted diluted per share amounts, EBITDA, adjusted EBITDA, adjusted income tax expense, free cash flow, net debt, and leverage ratio. The non-GAAP financial measures disclosed by the Company exclude certain business combination accounting adjustments and certain other items related to acquisitions, certain equity compensation, nonqualified deferred compensation plan expense (income), and certain one-time or unusual transactions. Detailed non-GAAP adjustments are described in the reconciliation tables below and also explained in the related footnotes. These non-GAAP financial measures should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations from these results should be carefully evaluated. Investors should not consider non-GAAP measures as alternatives to the related GAAP measures.
Set forth below are reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures.
(unaudited) Reconciliation of GAAP Effective Income Tax Rate to Non-GAAP Effective Income Tax Rate
(1)Amortization of intangible assets and finance leases: Amortization of intangible assets and finance leases consists of amortization of customer relationships, trademarks and trade names, developed technology, regulatory registration costs, patents and trade secrets, capitalized loan issuance costs, other intangibles acquired primarily in connection with business combinations, and finance leases. We record expense relating to the amortization of these intangibles and finance leases in our GAAP financial statements. Amortization expenses for our intangible assets and finance leases are inconsistent in amount and are significantly impacted by the timing and valuation of acquisitions. Consequently, our non-GAAP adjustments exclude these expenses to facilitate an evaluation of our current operating performance and comparisons to our past operating performance. (2)Transaction and integration costs: Transaction and integration costs related to acquisitions and divestitures are expensed in our GAAP financial statements. Management excludes these items for the purposes of calculating adjusted EBITDA and other non-GAAP financial measures. We believe that excluding these items from our non-GAAP financial measures is useful to investors because these are items associated with transactions that are inconsistent in amount and frequency causing comparison of current and historical financial results to be difficult. (3)Nonqualified deferred compensation plan (income) expense: Gains and losses on rabbi trust assets related to our nonqualified deferred compensation plan are recorded in other (income) expense while the offsetting increases or decreases to the deferred compensation liability are recorded within earnings from operations. The increases and decreases in the deferred compensation liability are driven by market volatility and are not a true reflection of company performance. We believe excluding these amounts from our non-GAAP financial measures is useful to investors because these items are inconsistent in amount based on market conditions causing comparison of current and historical financial results to be difficult. (4)Restructuring costs: Restructuring costs related to a reorganization of the business are recorded in our GAAP financial statements. Management excludes these items for the purposes of calculating adjusted EBITDA and other non-GAAP financial measures. We believe that excluding these items from our non-GAAP financial measures is useful to investors because these items are inconsistent in amount and frequency causing comparison of current and historical financial results to be difficult. (5)Income tax adjustment: For purposes of calculating adjusted net earnings and adjusted diluted earnings per share, we adjust the provision for (benefit from) income taxes to tax effect the taxable and deductible non-GAAP adjustments described above as they have a significant impact on our income tax (benefit) provision. Additionally, the income tax adjustment is adjusted for the impact of adopting ASU 2016-09, “Improvements to Employee Share-Based Payment Accounting” and uses our non-GAAP effective rate applied to both our GAAP earnings before income tax expense and non-GAAP adjustments described above. See Table 3 for the calculation of our non-GAAP effective tax rate. (6)Impact of ASU 2016-09: The primary impact of ASU No. 2016-09, "Improvements to Employee Share-Based Payment Accounting" ("ASU 2016-09"), was the recognition during the three and nine months ended September 30, 2026 and 2025, of excess tax benefits as a reduction to the provision for income taxes and the classification of these excess tax benefits in operating activities in the consolidated statement of cash flows instead of financing activities. Management excludes this item for the purpose of calculating adjusted Income Tax Expense. We believe that excluding the item in our non-GAAP financial measures is useful to investors because it is inconsistent in amount and frequency causing comparison of current and historical financial results to be difficult.
Full text with the tables
Exhibit 99.1
Human Nutrition & Health | Animal Nutrition &
Health | Specialty Products
Balchem Corporation Reports Third Quarter 2026 Financial Results
Montvale, NJ, October 23, 2026 - Balchem Corporation (NASDAQ: BCPC) today
reported financial results for its 2026 fiscal third quarter ended September 30,
2026. For the quarter, the Company reported net sales of $290.7 million, net
earnings of $46.7 million, adjusted EBITDA (a) of $80.3 million, and free c ash
flow (a) of $57.9 million.
Ted Harris, Chairman, President and CEO of Balchem, said, “Balchem delivered
another excellent quarter, with healthy growth across all three of our reporting
segments and record consolidated quarterly net sales, net earnings, and adjusted
EBITDA.”
Third Quarter 2026 Financial Highlights:
• Net sales were $290.7 million, an increase of 8.6% from the prior year
quarter.
• GAAP net earnings were $46.7 million, an increase of 16.0% from the prior year
quarter.
• Adjusted EBITDA was $80.3 million, an increase of 12.4% from the prior year
quarter.
• GAAP earnings per share were $1.46 compared to $1.24 in the prior year quarter
and adjusted earnings per share (a) were $1.57 compared to $1.35 in the prior
year quarter.
• Cash flows from operations were $69.8 million, with free cash flow of $57.9
million.
• Sales and earnings from operations growth in all three of our reporting
segments.
Recent Highlights:
• At the upcoming SupplySide Global trade show, we will showcase several of our
latest Human Nutrition and Health technologies and innovations, including new
science supporting VitaCholine ® , K2VITAL ™ , Optifolin+ ® and OptiMSM ® , as
well as advances in performance nutrition and functional food and beverage
applications. These innovations highlight the strength of our pipeline and our
continued focus on developing differentiated, science-backed solutions that
address important human health and wellness trends.
• Balchem repurchased approximately $28 million of common stock during the third
quarter and approximately $127 million over the trailing twelve months,
reflecting the Company's balanced capital allocation strategy and commitment to
long-term shareholder value creation.
Mr. Harris added, “With strong results through the first nine months of the year
and a healthy balance sheet, Balchem is well positioned to continue executing
our strategic growth initiatives, and we remain excited about the future of our
company.”
5 Paragon Drive p.845.326.5600
Montvale, NJ 07645 f.845.326.5702
balchem.com
Balchem Corporation (NASDAQ:BCPC)
Results for Period Ended September 30, 2026 (unaudited)
(Dollars in thousands, except per share data)
Three Nine
Months Months
Ended Ended
Septem… Septemb…
2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Net $ 290,658 $ 267,558 $ 845,364 $ 773,544
sales
Gross 105,714 95,453 310,481 276,734
margin
Operat… 43,277 40,874 133,197 119,698
expens…
Earnin…
from 62,437 54,579 177,284 157,036
operat…
Intere…
and 2,393 2,535 6,937 8,041
other
expens…
Earnin…
before
income 60,044 52,044 170,347 148,995
tax
expense
Income
tax 13,316 11,755 38,719 33,375
expense
Net $ 46,728 $ 40,289 $ 131,628 $ 115,620
earnin…
Diluted
net
earnin… $ 1.46 $ 1.24 $ 4.09 $ 3.54
per
common
share
Adjust… $ 80,297 $ 71,447 $ 232,522 $ 206,961
EBITDA…
Adjust…
net $ 50,350 $ 43,982 $ 141,437 $ 125,560
earnin…
Adjust…
net
earnin… $ 1.57 $ 1.35 $ 4.40 $ 3.84
per
common
share(…
Shares
used in
the
calcul…
of
diluted
and 32,032 32,595 32,181 32,702
adjust…
net
earnin…
per
common
share
(a) See “Non-GAAP Financial Information” for a reconciliation of GAAP and
non-GAAP financial measures.
Page | 2
Balchem Corporation (NASDAQ:BCPC)
Financial Results for the Third Quarter of 2026:
The
Human Nutrition and Health
segment generated record quarterly sales of $188.2 million, an increase of $14.1
million, or 8.1%, compared to the prior year quarter. The increase was driven by
higher sales within both the nutrients business and the food ingredients and
solutions businesses. Record earnings from operations for this segment of $45.6
million increased $4.8 million, or 11.8%, compared to $40.8 million in the prior
year quarter, primarily due to the aforementioned higher sales and favorable
mix, partially offset by higher operating expenses. Excluding the effect of non-
cash expense associated with amortization of acquired intangible assets and
other adjustments, record adjusted earnings from operations (a) for this segment
were $48.9 million, compared to $44.1 million in the prior year quarter, an
increase of 10.9%.
The
Animal Nutrition and Health
segment generated quarterly sales of $63.0 million, an increase of $6.6 million,
or 11.7%, compared to the prior year quarter. The increase was driven by higher
sales in both the monogastric and ruminant species markets. Third quarter
earnings from operations for this segment of $6.8 million increased $3.1
million, or 82.8%, compared to $3.7 million in the prior year quarter, primarily
due to the aforementioned higher sales and favorable mix, partially offset by
certain higher manufacturing input costs. Excluding the effect of non-cash
expense associated with amortization of acquired intangible assets and other
adjustments, adjusted earnings from operations for this segment were $7.0
million compared to $4.0 million in the prior year quarter, an increase of
73.6%.
The
Specialty Products
segment generated quarterly sales of $37.3 million, an increase of $1.6 million,
or 4.5%, compared to the prior year quarter, due to higher sales in the
performance gases business. Earnings from operations for this segment of $12.3
million increased $0.8 million, or 6.6%, compared to $11.5 million in the prior
year quarter, primarily driven by the aforementioned higher sales and favorable
mix, partially offset by higher operating expenses. Excluding the effect of non-
cash expense associated with amortization of acquired intangible assets and
other adjustments, adjusted earnings from operations for this segment were $13.1
million, compared to $12.7 million in the prior year quarter, an increase of
3.0%.
Consolidated quarterly gross margin of $105.7 million increased by $10.3
million, or 10.7%, compared to $95.5 million for the prior year comparable
period. Gross margin as a percentage of sales was 36.4% compared to 35.7% in the
prior year period, an increase of 70 basis points, primarily due to sales
growth, favorable mix and manufacturing efficiencies, partially offset by
certain higher manufacturing input costs. Operating expenses of $43.3 million
for the quarter increased $2.4 million from the prior year comparable quarter,
primarily due to higher compensation-related costs, partially offset by the net
favorable impact of certain discrete items.
Net interest expense was $1.9 million and $2.6 million in the third quarters of
2026 and 2025, respectively. The decrease in interest expense was primarily due
to lower outstanding borrowings and lower interest rates. Our effective tax
rates for the three months ended September 30, 2026 and 2025 were 22.2% a nd
22.6%, respectively . The decrease in the effective tax rate was primarily d ue
to higher favorable adjustments related to the filing of the prior year federal
tax return and a higher foreign-derived intangible income deduction benefit,
partially offset by an increase in certain state taxes.
Third quarter cash flows provided by operating activities were $69.8 million and
free cash flow was $57.9 million. Net working capital of $240.8 million as of
September 30, 2026 included a cash balance of $66.3 million. Significant cash
payments during the quarter included net debt payments of $28.0 million, income
taxes paid of $27.8 million, repurchases of common stock of $27.4 million, and
capital expenditures and intangible assets acquired of $12.5 million.
Outstanding debt on our revolving loan was $124.0 million as of September 30,
2026 and our net debt (b) was $57.7 million, with an overall leverage ratio (c)
on a net debt basis of 0.2 times.
Mr. Harris said, “The Balchem team delivered another strong quarter in Q3 of
2026, and we remain confident in the long-term growth outlook for our company as
we continue to execute our strategic growth initiatives.”
(b) Net debt is defined as the outstanding balance on our revolving loan
less cash and cash equivalents.
(c) Leverage ratio is defined as net debt divided by trailing twelve
months adjusted EBITDA.
Page | 3
Balchem Corporation (NASDAQ:BCPC)
Quarterly Conference Call
A quarterly conference call will be held on Friday, October 23, 2026, at 11:00
AM Eastern Time (ET) to review third quarter 2026 results. Ted Harris, Chairman,
President and CEO and Martin Bengtsson, CFO, will host the call. Institutional
investors, analysts and other members of the financial community are invited to
join the live call by dialing +1-833-461-5787 (USA/Canada toll free) or
+1-585-542-9983 (International Toll), and referencing Meeting ID: 831870284,
five minutes prior to the scheduled start time of the conference call. Investors
and the public are invited to listen to the live webcast at
https://events.q4inc.com/attendee/831870284. The conference call will be
available for replay shortly after the conclusion of the call at
https://events.q4inc.com/attendee/831870284 for one year.
Segment Information
Balchem Corporation reports three business segments: Human Nutrition and Health,
Animal Nutrition and Health, and Specialty Products. The Human Nutrition and
Health segment delivers customized food and beverage ingredient systems, as well
as key nutrients into a variety of applications across the food, supplement and
pharmaceutical industries. The Animal Nutrition and Health segment manufactures
and supplies products to numerous animal health markets. Through Specialty
Products, Balchem provides specialty-packaged performance gases for use in
healthcare and other industries, and also provides chelated minerals to the
micronutrient agricultural market. Sales and production of products outside of
our reportable segments and other minor business activities are included in
"Other and Unallocated".
Forward-Looking Statements
This release contains forward-looking statements, within the meaning of the
Private Securities Litigation Reform Act of 1995, Section 27A of the Securities
Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended,
which reflect our expectation or belief concerning future events that involve
risks and uncertainties. These forward-looking statements generally are
identified by the words "believe," "project," "expect," "anticipate,"
"estimate," "forecast," "outlook," "intend," "strategy," "future,"
"opportunity," "plan," "may," "should," "will," "would," "will be," "will
continue," "will likely result," or the negative thereof or variations thereon
or similar expressions generally intended to identify forward-looking
statements. Forward-looking statements may relate to such matters as projections
of revenue, margins, expenses, tax provisions, earnings, cash flows, benefit
obligations, dividends, share repurchases or other financial items; any
statements of the plans, strategies and objectives of management for future
operations, including those relating to any statements concerning expected
development, performance or market share relating to our products and services;
any statements regarding future economic conditions or our performance; any
statements regarding pending investigations, claims or disputes; any statements
of expectation or belief; and any statements of assumptions underlying any of
the foregoing. These statements are based on the Company's currently available
information and our current assumptions, expectations and projections about
future events. They are subject to future events, risks and uncertainties - many
of which are beyond the Company’s control - as well as potentially inaccurate
assumptions, that could cause actual results to differ materially from those in
the forward-looking statements. Important factors and other risks that may
affect the Company's business or that could cause actual results to differ
materially are included in filings the Company makes with the U.S. Securities
and Exchange Commission from time to time, including its Annual Report on Form
10-K, its Quarterly Reports on Form 10-Q, its Current Reports on Form 8-K, and
in its other SEC filings. Reference should be made to such factors and all
forward-looking statements are qualified in their entirety by the above
cautionary statements. The Company undertakes no obligation to publicly update
or revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact: Jacqueline Yarmolowicz, Balchem Corporation (Telephone: 845-326-5600)
Page | 4
Balchem Corporation (NASDAQ:BCPC)
Selected Financial Data (unaudited)
($ in 000’s)
Three Nine
Busin… Months Months
Segme… Ended Ended
Net Septe… Septem…
Sales: 2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Human
Nutr… $ 188,2… $ 174,0… $ 536,749 $ 493,3…
and
Heal…
Anim…
Nutr… 62,990 56,376 189,633 169,6…
and
Heal…
Spec… 37,294 35,683 112,532 106,1…
Prod…
Othe… 2,147 1,411 6,450 4,402
Total $ 290,6… $ 267,5… $ 845,364 $ 773,5…
(d)O…
cons…
of a
few
minor
busi…
which
indi…
do
not
meet
the
quan…
thre…
for
sepa…
pres…
Busin…
Segme… Three Nine
Earni… Months Months
Before Ended Ended
Income Septe… Septem…
Taxes: 2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Human
Nutr… $ 45,633 $ 40,831 $ 128,034 $ 117,1…
and
Heal…
Anim…
Nutr… 6,789 3,713 17,708 12,463
and
Heal…
Spec… 12,301 11,534 37,129 32,388
Prod…
Other
and -2,286 -1,499 -5,587 -4,962
Unal…
Inte…
and -2,393 -2,535 -6,937 -8,041
other
expe…
Total $ 60,044 $ 52,044 $ 170,347 $ 148,9…
(e)O…
and
Unal…
cons…
of a
few
minor
busi…
which
indi…
do
not
meet
the
quan…
thre…
for
sepa…
pres…
and
corp…
expe…
that
have
not
been
allo…
to
a
segm…
Unal…
corp…
expe…
cons…
of
tran…
and
inte…
cost…
$578
and
$1,4…
three
and
nine
mont…
ended
Sept…
30,
2026,
resp…
and
$333
and
$1,2…
for
the
three
and
nine
mont…
ended
Sept…
30,
2025,
resp…
Page | 5
Balchem Corporation (NASDAQ:BCPC)
Selected
Balance Sheet (Dollars in September 30, December 31,
Items thousands) 2026 2025
──────────────────────────────────────────────────────────────────────────────
-unaudited
Cash and cash $ 66,264 $ 74,570
equivalents
Accounts
receivable, 145,635 143,596
net
Inventories 177,006 131,449
Other current 15,972 15,999
assets
Total current 404,877 365,614
assets
Property,
plant and 306,135 306,648
equipment,
net
Goodwill 807,487 816,375
Intangible
assets with 147,366 163,289
finite lives,
net
Right of use 17,683 16,192
assets
Other assets 20,024 18,134
Total
non-current 1,298,695 1,320,638
assets
Total assets $ 1,703,572 $ 1,686,252
Current $ 164,115 $ 176,384
liabilities
Revolving 124,000 164,000
loan
Deferred 52,273 54,143
income taxes
Other
long-term 36,407 34,312
obligations
Total 376,795 428,839
liabilities
Stockholders' 1,326,777 1,257,413
equity
Total
liabilities
and $ 1,703,572 $ 1,686,252
stockholders'
equity
Page | 6
Balchem Corporation (NASDAQ:BCPC)
Balchem Corporation
Condensed Consolidated Statements of Cash Flows
(Dollars in thousands)
(unaudited)
Nine Months Ended
Cash flows from September 30,
operating activities: 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net earnings $ 131,628 $ 115,620
Adjustments to
reconcile net earnings
to net cash provided
by operating
activities:
Depreciation and 37,100 33,969
amortization
Stock compensation 16,316 14,298
expense
Other adjustments 3,037 -1,692
Changes in assets and -31,537 -12,914
liabilities
Net cash provided by
operating 156,544 149,281
activities
Cash flows from
investing activities:
Capital expenditures
and intangible -29,605 -27,275
assets acquired
Cash paid for
acquisitions, net of — -323
cash
acquired
Proceeds from the sale 7 267
of assets
Investment in -155 -144
affiliates
Net cash used in -29,753 -27,475
investing activities
Cash flows from
financing activities:
Proceeds from 88,000 70,000
revolving loan
Principal payments on -128,000 -106,000
revolving loan
Principal payments on -153 -145
finance leases
Cash paid for -1,943 —
financing costs
Proceeds from stock 11,589 6,867
options exercised
Dividends paid -30,773 -28,276
Repurchases of common -71,925 -54,008
stock
Net cash used in -133,205 -111,562
financing activities
Effect of exchange -1,892 5,334
rate changes on cash
(Decrease) increase in
cash and cash -8,306 15,578
equivalents
Cash and cash
equivalents, beginning 74,570 49,515
of
period
Cash and cash
equivalents, end of $ 66,264 $ 65,093
period
Page | 7
Balchem Corporation (NASDAQ:BCPC)
Non-GAAP Financial Information
In addition to disclosing financial results in accordance with United States
(U.S.) generally accepted accounting principles (GAAP), this earnings release
contains non-GAAP financial measures that we believe are helpful in
understanding and comparing our past financial performance and our future
results. The non-GAAP financial measures in this press release include adjusted
gross margin, adjusted earnings from operations, adjusted net earnings and the
related adjusted diluted per share amounts, EBITDA, adjusted EBITDA, adjusted
income tax expense, free cash flow, net debt, and leverage ratio. The non-GAAP
financial measures disclosed by the Company exclude certain business combination
accounting adjustments and certain other items related to acquisitions, certain
equity compensation, nonqualified deferred compensation plan expense (income),
and certain one-time or unusual transactions. Detailed non-GAAP adjustments are
described in the reconciliation tables below and also explained in the related
footnotes. These non-GAAP financial measures should not be considered a
substitute for, or superior to, financial measures calculated in accordance with
GAAP, and the financial results calculated in accordance with GAAP and
reconciliations from these results should be carefully evaluated. Investors
should not consider non-GAAP measures as alternatives to the related GAAP
measures.
Set forth below are reconciliations of the non-GAAP financial measures to the
most directly comparable GAAP financial measures.
Table 1
(unaudited)
Reconciliation of Non-GAAP Measures to GAAP
(Dollars in thousands, except per share data)
Three Nine
Recon… Months Months
of Ended Ended
adjus… Septe… Septe…
gross 30, 30,
margin 2026 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
GAAP
gross $ 105,714 $ 95,453 $ 310,481 $ 276,7…
margin
Amort…
of
intan…
assets 715 739 2,162 2,156
and
finan…
lease…
Adjus…
gross $ 106,429 $ 96,192 $ 312,643 $ 278,8…
margin
Recon…
of
adjus…
earni…
from
opera…
GAAP
earni… $ 62,437 $ 54,579 $ 177,284 $ 157,0…
from
opera…
Amort…
of
intan…
assets 4,333 4,394 13,137 12,819
and
finan…
lease…
Trans…
and 578 333 1,495 1,227
integ…
costs…
Nonqu…
defer…
compe… -45 404 572 839
plan
expen…
Restr… — — — -192
costs…
Adjus…
earni… $ 67,303 $ 59,710 $ 192,488 $ 171,7…
from
opera…
Recon…
of
adjus…
net
earni…
GAAP
net $ 46,728 $ 40,289 $ 131,628 $ 115,6…
earni…
Amort…
of
intan…
assets 4,433 4,467 13,381 13,035
and
finan…
lease…
Trans…
and 578 333 1,495 1,227
integ…
costs…
Restr… — — — -192
costs…
Income
tax -1,389 -1,107 -5,067 -4,130
adjus…
Adjus…
net $ 50,350 $ 43,982 $ 141,437 $ 125,5…
earni…
Adjus…
net
earni…
per $ 1.57 $ 1.35 $ 4.40 $ 3.84
common
share
-
dilut…
Page | 8
Balchem Corporation (NASDAQ:BCPC)
Table 2
(unaudited)
Reconciliation of GAAP Net Earnings to EBITDA and to Adjusted EBITDA
(Dollars in thousands)
Th… Nine
Mo… Mon…
En… End…
Se… Sep…
20… 30, 20… 20… 30, 2025
──────────────────────────────────────────────────────────────────────────────
N…
e…
- $ 46… $ 40… $ 13… $ 11…
as
r…
A…
b…
P…
f… 13… 11… 38… 33…
i…
t…
I…
a… 2,… 2,… 6,… 8,…
o…
e…
D…
a… 12… 11… 36… 33…
a…
E… 74… 66… 21… 19…
A…
b…
N…
c…
e…
r… 5,… 4,… 16… 14…
to
e…
a…
T…
a… 578 333 1,… 1,…
i…
c…
N…
d…
c… -45 404 572 839
p…
e…
R… — — — -1…
c…
A… $ 80… $ 71… $ 23… $ 20…
E…
Table 3
(unaudited)
Reconciliation of GAAP Effective Income Tax Rate to Non-GAAP Effective Income
Tax Rate
(Dollars in thousands)
Thr…
Mon…
End… Eff… Eff…
Sep… Tax Tax
2026 30, Rate 2025 Rate
──────────────────────────────────────────────────────────────────────────────
GA…
In… $ 13… 22… % $ 11… 22… %
Tax
Ex…
Im…
of 260 21
ASU
20…
Ad…
In… $ 13… 22… % $ 11… 22… %
Tax
Ex…
Nine
Mon…
End… Eff… Eff…
Sep… Tax Tax
2026 30, Rate 2025 Rate
──────────────────────────────────────────────────────────────────────────────
GA…
In… $ 38… 22… % $ 33… 22… %
Tax
Ex…
Im…
of 1,… 894
ASU
20…
Ad…
In… $ 40… 23… % $ 34… 23… %
Tax
Ex…
Page | 9
Balchem Corporation (NASDAQ:BCPC)
Table 4
(unaudited)
Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow
(Dollars in thousands)
Three Nine
Months Months
Ended Ended
Septem… Septemb…
2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Net
cash
provid… $ 69,772 $ 65,572 $ 156,544 $ 149,281
by
operat…
activi…
Capital
expend…
and
procee… -11,863 -14,891 -28,559 -26,866
from
the
sale of
assets
Free
cash $ 57,909 $ 50,681 $ 127,985 $ 122,415
flow
(1)Amortization of intangible assets and finance
leases:
Amortization of intangible assets and finance
leases consists of amortization of customer
relationships, trademarks and trade names,
developed technology, regulatory registration
costs, patents and trade secrets, capitalized loan
issuance costs, other intangibles acquired
primarily in connection with business
combinations, and finance leases. We record
expense relating to the amortization of these
intangibles and finance leases in our GAAP
financial statements. Amortization expenses for
our intangible assets and finance leases are
inconsistent in amount and are significantly
impacted by the timing and valuation of
acquisitions. Consequently, our non-GAAP
adjustments exclude these expenses to facilitate
an evaluation of our current operating performance
and comparisons to our past operating performance.
(2)Transaction and integration costs: Transaction
and integration costs related to acquisitions and
divestitures are expensed in our GAAP financial
statements. Management excludes these items for
the purposes of calculating adjusted EBITDA and
other non-GAAP financial measures. We believe that
excluding these items from our non-GAAP financial
measures is useful to investors because these are
items associated with transactions that are
inconsistent in amount and frequency causing
comparison of current and historical financial
results to be difficult.
(3)Nonqualified deferred compensation plan
(income) expense: Gains and losses on rabbi trust
assets related to our nonqualified deferred
compensation plan are recorded in other (income)
expense while the offsetting increases or
decreases to the deferred compensation liability
are recorded within earnings from operations. The
increases and decreases in the deferred
compensation liability are driven by market
volatility and are not a true reflection of
company performance. We believe excluding these
amounts from our non-GAAP financial measures is
useful to investors because these items are
inconsistent in amount based on market conditions
causing comparison of current and historical
financial results to be difficult.
(4)Restructuring costs: Restructuring costs
related to a reorganization of the business are
recorded in our GAAP financial statements.
Management excludes these items for the purposes
of calculating adjusted EBITDA and other non-GAAP
financial measures. We believe that excluding
these items from our non-GAAP financial measures
is useful to investors because these items are
inconsistent in amount and frequency causing
comparison of current and historical financial
results to be difficult.
(5)Income tax adjustment:
For purposes of calculating adjusted net earnings
and adjusted diluted earnings per share, we adjust
the provision for (benefit from) income taxes to
tax effect the taxable and deductible non-GAAP
adjustments described above as they have a
significant impact on our income tax (benefit)
provision. Additionally, the income tax adjustment
is adjusted for the impact of adopting ASU
2016-09, “Improvements to Employee Share-Based
Payment Accounting” and uses our non-GAAP
effective rate applied to both our GAAP earnings
before income tax expense and non-GAAP adjustments
described above. See Table 3 for the calculation
of our non-GAAP effective tax rate.
(6)Impact of ASU 2016-09:
The primary impact of ASU No. 2016-09,
"Improvements to Employee Share-Based Payment
Accounting" ("ASU 2016-09"), was the recognition
during the three and nine months ended September
30, 2026 and 2025, of excess tax benefits as a
reduction to the provision for income taxes and
the classification of these excess tax benefits in
operating activities in the consolidated statement
of cash flows instead of financing activities.
Management excludes this item for the purpose of
calculating adjusted Income Tax Expense. We
believe that excluding the item in our non-GAAP
financial measures is useful to investors because
it is inconsistent in amount and frequency causing
comparison of current and historical financial
results to be difficult.
Page | 10